{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:16Z","timestamp":1790236636402,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:50:35Z","timestamp":1743457835000},"page":"e875-e885.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice"],"prefix":"10.1016","volume":"25","author":[{"given":"Sophia S.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-5643","authenticated-orcid":false,"given":"Anita","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-5200","authenticated-orcid":false,"given":"Irina","family":"Pivneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talissa","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-0812","authenticated-orcid":false,"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.03.012_bib0001","unstructured":"National Organization for Rare Disorders I. Amyloidosis. 2024; https:\/\/rarediseases.org\/rare-diseases\/amyloidosis\/. Accessed January 17, 2024."},{"issue":"17","key":"10.1016\/j.clml.2025.03.012_bib0002","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood.2021012973","article-title":"Why is amyloidosis not multiple myeloma?","volume":"138","author":"Corre","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.03.012_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.03.012_bib0004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40265-022-01830-z","article-title":"Diagnosis and treatment of AL amyloidosis","volume":"83","author":"Palladini","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clml.2025.03.012_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.clml.2025.03.012_bib0006","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","article-title":"The patient's perspective on the symptom and everyday life impact of AL amyloidosis","volume":"22","author":"Lin","year":"2015","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.clml.2025.03.012_bib0007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11899-020-00574-5","article-title":"Updates in the diagnosis and management of AL amyloidosis","volume":"15","author":"Cook","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.clml.2025.03.012_bib0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.22.00396","article-title":"Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation","volume":"19","author":"Dima","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2025.03.012_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/hemato3010004","article-title":"Beyond survival in AL amyloidosis: identifying and satisfying patients\u2019 needs","volume":"3","author":"Hassan","year":"2022","journal-title":"Hemato"},{"issue":"5","key":"10.1016\/j.clml.2025.03.012_bib0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.03.012_bib0011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2025.03.012_bib0012","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ejh.13993","article-title":"Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies","volume":"111","author":"Fotiou","year":"2023","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.03.012_bib0013","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-chain) cardiac Amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2025.03.012_bib0014","doi-asserted-by":"crossref","first-page":"384","DOI":"10.18632\/oncotarget.28415","article-title":"Systemic AL amyloidosis: current approach and future direction","volume":"14","author":"Bou Zerdan","year":"2023","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.clml.2025.03.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3143.3143","article-title":"Risk of progression of localised amyloidosis to systemic disease In 606 patients over 30 years","volume":"122","author":"Mahmood","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.012_bib0016","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.03.012_bib0017","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.amjms.2022.12.009","article-title":"Ethnic\/racial differences in risk factors and clinical outcomes among patients with amyloidosis","volume":"365","author":"Ream","year":"2023","journal-title":"Am J Med Sci"},{"issue":"11","key":"10.1016\/j.clml.2025.03.012_bib0018","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","article-title":"Race\/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities","volume":"10","author":"Staron","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.03.012_bib0019","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.03.012_bib0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-023-00945-0","article-title":"Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies","volume":"13","author":"Bal","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.03.012_bib0021","first-page":"5333","article-title":"Translocation (11;14) and survival of patients with AL amyloidosis and multiple myeloma","volume":"130","author":"Yogo","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.012_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-022-00697-3","article-title":"Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans","volume":"12","author":"Staron","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2025.03.012_bib0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13506129.2022.2137400","article-title":"Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases","volume":"30","author":"Dispenzieri","year":"2023","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.clml.2025.03.012_bib0024","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/jha2.562","article-title":"Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: a population-based cohort study","volume":"3","author":"Jimenez-Zepeda","year":"2022","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.clml.2025.03.012_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","article-title":"The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018","volume":"13","author":"Palladini","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.03.012_bib0026","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1182\/blood-2023-187073","article-title":"Treatment patterns and outcomes of patients with light chain (AL) amyloidosis: analysis of a large US claims database","volume":"142","author":"Lyon","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.03.012_bib0027","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1182\/blood-2023-190292","article-title":"Real-world treatment patterns following update to National Comprehensive Cancer Network Guidelines for light-chain amyloidosis: results from a US administrative claims database","volume":"142","author":"Thomspon","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.03.012_bib0028","unstructured":"(FDA). UFaDA. US Food and Drug Administration (FDA). FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. 2021; https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis, 2024. Accessed 23 January, 2024."},{"issue":"22","key":"10.1016\/j.clml.2025.03.012_bib0029","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V128.22.3559.3559","article-title":"Treatment patterns and clinical outcomes among patients with newly diagnosed and relapsed\/refractory sytemic light chain amyloidosis","volume":"128","author":"Lin","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.03.012_bib0030","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood.2021014613","article-title":"Daratumumab in AL amyloidosis","volume":"140","author":"Wechalekar","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:38:40Z","timestamp":1776397120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025001077"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}